{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-020615","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2024-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.105555+00:00","generated_at":"2026-06-01T04:00:37.673579+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"GeoVax receives BARDA award up to $45M for Phase 2b COVID-19 vaccine trial","bullets":["Direct award to GeoVax of ~$24.3M, potentially increasing to $45M, for manufacturing and clinical trial support.","BARDA separately commits ~$343M from Project NextGen for a CRO to execute the 10,000-participant Phase 2b study.","Phase 2b double-blinded trial will compare GeoVax's GEO-CM04S1 against an FDA-approved mRNA COVID-19 vaccine.","Study is part of HHS Project NextGen, a $5B initiative for next-generation COVID-19 vaccines and therapeutics.","GeoVax's dual-antigen vaccine candidate aims to induce durable antibody and T-cell immunity against variants."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-020615","json":"https://secwatch.observer/filing/0001437749-24-020615.json","markdown":"https://secwatch.observer/filing/0001437749-24-020615.md","text":"https://secwatch.observer/filing/0001437749-24-020615.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774924020615/0001437749-24-020615-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774924020615/govx20240618_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:00:37.673579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}